John Sullivan Net Worth

The estimated Net Worth of John F Sullivan is at least $2.07 million dollars as of 30 August 2021. Mr. Sullivan owns over 3,200 units of TransMedics stock worth over $2,052,600 and over the last 6 years he sold TMDX stock worth over $17,990. In addition, he makes $0 as Vice President - Quality and Engineering at TransMedics.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Sullivan TMDX stock SEC Form 4 insiders trading

John has made over 7 trades of the TransMedics stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 3,200 units of TMDX stock worth $896 on 30 August 2021.

The largest trade he's ever made was exercising 15,000 units of TransMedics stock on 7 April 2021 worth over $75,000. On average, John trades about 4,282 units every 65 days since 2019. As of 30 August 2021 he still owns at least 14,273 units of TransMedics stock.

You can see the complete history of Mr. Sullivan stock trades at the bottom of the page.

John Sullivan biography

John Sullivan serves as Vice President - Quality and Engineering of the Company. Prior to joining TransMedics, Mr. Sullivan served as Software Development Manager at Juniper Networks and designed patient monitoring systems at Siemens Medical Systems USA, Inc. He has also held a number of roles at startups and established companies, including ViaSat, Inc., Argon Networks and Raytheon Company. Mr. Sullivan holds a Bachelor’s degree in Electrical Engineering and Computer Science from Princeton University and a M.S. in Computer Engineering from Boston University.

How old is John Sullivan?

John Sullivan is 55, he's been the Vice President - Quality and Engineering of TransMedics since 2019. There are 8 older and 7 younger executives at TransMedics. The oldest executive at TransMedics Group, Inc. is James Tobin, 75, who is the Independent Chairman of the Board.

What's John Sullivan's mailing address?

John's mailing address filed with the SEC is C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, ANDOVER, MA, 01810.

Insiders trading at TransMedics

Over the last 6 years, insiders at TransMedics have traded over $99,976,312 worth of TransMedics stock and bought 154,333 units worth $3,250,328 . The most active insiders traders include Edwin M Jr Kania, Waleed H Hassanein et James R Tobin. On average, TransMedics executives and independent directors trade stock every 10 days with the average trade being worth of $2,982,476. The most recent stock trade was executed by Tamer I Khayal on 3 September 2024, trading 2,960 units of TMDX stock currently worth $98,065.

What does TransMedics do?

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.

Complete history of Mr. Sullivan stock trades at TransMedics

TransMedics executives and stock owners

TransMedics executives and other stock owners filed with the SEC include:

• Waleed Hassanein,
  President, Chief Executive Officer, Director
• Tamer Khayal,
  Chief Commercial Officer
• Dr. Waleed H. Hassanein,
  Founder, MD, CEO, Pres & Director
• Dr. Tamer I. Khayal,
  Chief Commercial Officer
• Stephen Gordon,
  CFO. Treasurer & Sec.
• Stephen Gordon,
  Chief Financial Officer, Treasurer, Secretary
• David Weill,
  Independent Director
• James Tobin,
  Independent Chairman of the Board
• Thomas Gunderson,
  Independent Director
• Edward Basile,
  Independent Director
• Edwin Kania,
  Independent Director
• John Sullivan,
  Vice President - Quality and Engineering
• Miriam Provost,
  Vice President - Global Regulatory Affairs
• Laura Damme,
  Vice President - Clinical Affairs
• John Carey,
  Vice President - Operations
• Susan Goodman,
  VP of HR
• Mark Anderson,
  Sr. Director of Technology Devel.
• Ike Okonkwo,
  VP of Fin. & Accounting
• John F. Carey,
  VP of Operations
• Therapeutics Corp Lung Biot...,
  
• Ventures Fund Iv General Pa...,
  
• Capital Management, L.P.Abr...,
  
• Merilee Raines,
  
• Capital Management, L.P.Abr...,
  
• Rakesh P. Godhani,
  Chief Digital Officer
• Nicholas Corcoran,
  See Remarks
• Stephanie Lovell,
  
• Anil P. Ranganath,
  See remarks